Regeneron and Sanofi’s checkpoint inhibitor Libtayo (cemiplimab-rwlc) won U.S. Food and Drug Administration approval for the first-line treatment of patients with advanced non-small cell lung cancer whose tumors have high PD-L1 expression.
The U.S. Food and Drug Administration approved Merck’s anti-PD-1 therapy Keytruda as monotherapy for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.
Researchers at Boston University and Signify confirmed that UV-C light effectively eradicates the SARS-CoV-2 virus.
Pluristem Therapeutics Inc. reported positive results from a series of studies in animals of the company’s placenta-based stem cell therapy to treat acute radiation syndrome (ARS).
Switzerland will introduce a monitoring system to assuage concerns about the potential health impact of fifth-generation (5G) mobile frequency emissions and smooth the cutting-edge technology’s rollout, the government said.
To prepare for radiological and nuclear emergencies, the U.S. Department of Health and Human Services (HSS) announced it will work with Argentum Medical LLC to repurpose the company’s commercial Silverlon technology for radiation injuries of the skin.